Keros Therapeutics (KROS) Return on Equity (2019 - 2025)
Historic Return on Equity for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to 0.09%.
- Keros Therapeutics' Return on Equity rose 4900.0% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 4900.0%. This contributed to the annual value of 0.41% for FY2024, which is 900.0% up from last year.
- Per Keros Therapeutics' latest filing, its Return on Equity stood at 0.09% for Q3 2025, which was up 4900.0% from 0.03% recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Return on Equity ranged from a high of 0.09% in Q3 2025 and a low of 0.54% during Q4 2023
- In the last 5 years, Keros Therapeutics' Return on Equity had a median value of 0.36% in 2022 and averaged 0.3%.
- As far as peak fluctuations go, Keros Therapeutics' Return on Equity plummeted by -11400bps in 2021, and later surged by 4900bps in 2025.
- Over the past 5 years, Keros Therapeutics' Return on Equity (Quarter) stood at 0.25% in 2021, then crashed by -59bps to 0.4% in 2022, then tumbled by -34bps to 0.54% in 2023, then surged by 37bps to 0.34% in 2024, then soared by 127bps to 0.09% in 2025.
- Its Return on Equity stands at 0.09% for Q3 2025, versus 0.03% for Q2 2025 and 0.01% for Q1 2025.